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Despite the increased use, comparative safety and efficacy of direct-acting
oral anticoagulants (DOACs) against warfarin have not been well studied
in kidney transplant recipients. In this single-center retrospective study, we
evaluated 197 adult kidney transplant recipients on DOAC or warfarin
between January 1, 2011, and June 30, 2018. The primary outcome was
incidence of major bleeding defined as a hemoglobin decrease ≥2 g/dl,
blood transfusion ≥2 units, or symptomatic bleeding in a critical area or
organ. Patients were initiated on anticoagulation therapy at a median of
6.5 years post-transplant and followed for a median of 12.3 months. The
rates of major bleeding were 7.2% per year with DOACs vs. 11.4% per year
with warfarin (Mantel–Cox P = 0.15). No difference was found in com-
posite bleeding, clinically relevant nonmajor bleeding, or thromboembolic
events between the groups. There was a lower incidence of major bleeding
with apixaban compared to all other anticoagulants (6.7% vs. 19.0%,
P = 0.027). After controlling for potential confounders, DOAC use was
not associated with an increased risk of major bleeding (HR 0.73, 95% CI
0.27–1.95). Further research is warranted to definitively determine whether
DOACs are effective and safe alternatives to warfarin for anticoagulation in
kidney transplant recipients.
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Introduction
Direct-acting oral anticoagulants (DOACs) have become
more commonly prescribed since the approval of dabiga-
tran in 2010 and have significantly impacted anticoagula-
tion management for venous thromboembolism (VTE)
and stroke prevention in atrial fibrillation [1]. Their unique
mechanism of action and pharmacokinetic properties pro-
vide advantages and disadvantages compared with the his-
torical oral anticoagulant of choice, warfarin [2].
Advantages include infrequent laboratory monitoring, and
predictable pharmacokinetic and pharmacodynamic char-
acteristics thereby allowing for fixed oral doses. Because
robust pharmacokinetics studies and clinical trials of these




novel agents are lacking in patients with severe renal
impairment, there is a hesitancy to use them in patients
with diminished renal function or end-stage renal disease
because of potentially increased bleeding risk.
The incidence of new-onset atrial arrhythmias after
kidney transplantation has previously been reported to
range from 2.6% to 7.6% [3,4]. Additionally, kidney
transplant recipients are at an increased risk for VTE pos-
sibly because of impaired fibrinolysis and a heightened
hypercoagulable state [5]. More importantly, the compli-
cations of atrial arrhythmias and VTEs can result in graft
failure, morbidity, and mortality [6]. Thus, medical man-
agement becomes crucial in this patient population.
While appealing to use, there are significant barriers to
the appropriate use of DOACs in the kidney transplant
population, including an accurate estimation of glomeru-
lar filtration rate (GFR) and drug–drug interactions. The
equations that are used to estimate GFR after kidney
transplantation are similar to that used in the general
population, without accounting for recipient and graft
related factors that may alter GFR, including, but not lim-
ited to coexisting diseases, selected medications, and graft
blood flow [7]. In a transplant population where true
renal function may be under or overestimated by conven-
tional methods to calculate GFR, DOACs may be inap-
propriately dosed. Furthermore, drug–drug interactions
including cytochrome P-450 (CYP) and P-glycoprotein
(P-gp) inhibitors can result in adverse drug events. Cal-
cineurin inhibitors (CNIs) such as cyclosporine and
tacrolimus are maintenance immunosuppressive agents
used to prevent rejection in the transplant population.
Cyclosporine is recognized as a moderate inhibitor of
CYP3A4 and P-gp and can potentially interact with sub-
strates of CYP3A4 and P-gp such as DOACs [8]. Other
medications including antiarrhythmics (e.g., amiodarone
and diltiazem) and antifungals (e.g., fluconazole and
voriconazole) that transplant patients may encounter
post-transplant also interact with DOACs and further
complicate anticoagulation management. The purpose of
our study was to compare the safety and efficacy of
DOACs to warfarin in kidney transplant recipients.
Materials and methods
Study design
This study was conducted as a single-center retrospec-
tive cohort study. The study cohort included adult kid-
ney transplant recipients from Michigan Medicine with
a functioning allograft who initiated DOAC therapy
(apixaban, dabigatran, or rivaroxaban) or warfarin after
transplantation between January 1, 2011, and June 30,
2018. Patients were excluded if any of the following cri-
teria were met: multi-organ transplant recipients, anti-
coagulation treatment initiation prior to
transplantation, patients with mechanical or prosthetic
valves, gastrointestinal bleeding within six months prior
to initiation of anticoagulation, anticoagulation indica-
tion other than VTE or atrial fibrillation, patients with
incomplete records, or those anticoagulated for less than
30 days (if not discontinued for bleeding event). This
study was approved by the Institutional Review Board
of University of Michigan Medical School
(HUM00092121).
The primary outcome of this study was the incidence
of major bleeding defined by the International Society
on Thrombosis and Haemostasis (ISTH): bleeding lead-
ing to a decrease in hemoglobin (Hgb) ≥2 g/dl at any
time point, transfusion of at least 2 units of blood, or
symptomatic bleeding in a critical area or organ (in-
tracranial, intraspinal, intraocular, pericardial, intraartic-
ular, intramuscular, or retroperitoneal bleed) [9]. If any
of the previously mentioned criteria were met and not
attributed to any other cause, it was determined that
the patient had a major bleed because of anticoagula-
tion therapy. The definition for clinically relevant non-
major bleeding (CRNMB) was also consistent with
ISTH recommendations: any sign or symptom of hem-
orrhage that does not fit the criteria for the ISTH defi-
nition of major bleeding but requires medical
intervention by a healthcare professional, leads to hospi-
talization or increased level of care, or prompts a face
to face (i.e., not just a telephone or electronic commu-
nication) evaluation [10]. Secondary outcomes included
composite bleeding (major bleeding and CRNMB),
new-onset or recurrent VTE, and new-onset stroke dur-
ing anticoagulation therapy. Other measurable outcomes
included drug–drug interactions and appropriate DOAC
dosing according to renal function and indication.
Appropriateness of dosing was defined by the U.S. Food
and Drug Administration prescribing information for
each DOAC [11-13]. A subanalysis was also planned to
examine major bleeding risk among the DOACs.
Patients were followed until major bleeding event, dis-
continuation of anticoagulation, death, or most recent
laboratory value (for patients currently on anticoagula-
tion), whichever occurred first. Since patients were fol-
lowed until a first major bleeding event, repeat bleeding
events would only be captured if a patient experienced
a CRNMB event prior to a major bleeding event. Bleed-
ing events were identified by reviewing Hgb values in
the routine post-transplant laboratories, reasons for
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emergency room visits and hospital admissions, and
searching the electronic medical records using the
search term “bleed.” Prior bleeding events were defined
as bleeding events reported in the past medical history
that had occurred prior to the initiation of anticoagula-
tion.
Institutional pharmacologic management
All kidney transplant patients received a maintenance
immunosuppression regimen consisting of tacrolimus
or cyclosporine, and mycophenolate mofetil with ster-
oids per institutional protocol at the time of transplan-
tation. Subsequent changes in maintenance
immunosuppressive regimens were individualized per
providers. The goal tacrolimus trough was 8–12 ng/ml
for the first 90 days post-transplant, 6–10 ng/ml during
days 91–120, and 4–8 ng/ml after postoperative day
120. The goal cyclosporine trough was 250–300 ng/ml
for postoperative days 0–90, 200–250 ng/ml for postop-
erative days 91–180, 150–200 ng/ml for postoperative
days 181–365, and 100–200 ng/ml after one year. Trans-
plant recipients were on fungal prophylaxis with oral
nystatin solution for 1 month, viral prophylaxis for 3–
6 months, and Pneumocystis jirovecii pneumonia pro-
phylaxis for 1 month post-transplantation.
Anticoagulation management was provider specific and
not according to an institutional protocol. Prior to
transplant listing, all patients received a routine colono-
scopy per protocol.
Statistical analysis
Normally distributed continuous variables were com-
pared using the Student’s t-tests and are presented as
mean  standard deviation (SD). Non-normally dis-
tributed continuous variables were analyzed using the
Mann–Whitney U tests and are presented as median
with interquartile range (IQR). Categorical variables are
presented in percentage and were compared utilizing
the chi-square or Fisher’s exact tests. Time to major
bleeding event was analyzed using the Kaplan–Meier
plot with the Mantel–Cox log-rank test to assess for dif-
ference between DOAC and warfarin groups. Cox pro-
portional hazards model on time to major bleeding
event was performed. This model considered DOAC use
versus warfarin and included potential confounders
identified by prior research. Calendar year of anticoagu-
lation initiation was also included to account for
unmeasured changes in practice and patient care over
time. The proportional hazards assumption was tested
using Schoenfeld residuals in the final model using chi-
Screened, n = 220
Adult kidney transplant recipients who initiated 
oral anticoagulation post-transplant for atrial 
fibrillation or venous thromboembolism 
between January 1, 2011, and June 30, 2018 
Warfarin, n = 98
DOAC, n = 99
Apixaban, n = 60
Dabigatran, n = 6
Rivaroxaban, n = 33
Excluded, n = 23
Valve replacement, n = 9
Gastrointestinal bleed within 6 months, n = 3
Anticoagulation for less than 30 days (if not 
stopped for bleed) or loss to follow up/ 
incomplete records, n = 11
Figure 1 Study design.
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square test [14,15]. In a sensitivity analysis, we ran the
same model excluding those with prior bleeding epi-
sodes. Results were considered significant with a two-
sided P-value <0.05. Statistical analyses were performed
using IBM SPSS version 24 (IBM Corp., Armonk, NY,
USA) and R version 3.6.1 [16].
Results
Patients
A total of 197 kidney transplant recipients were
included in this study (Fig. 1). Patients were initiated
on warfarin or DOAC therapy at a median of 6.5 (IQR
2.6–11.2) years post-transplant and followed for a med-
ian of 12.3 (IQR 5.2–27.5) months on anticoagulation.
Despite that no formal matching was done, the two
groups had similar baseline demographics and clinical
characteristics (Table 1). The only differences were Hgb,
concomitant antiplatelet use at time of anticoagulation
initiation, and calendar year of anticoagulation initia-
tion.
Safety and efficacy
There was no difference in major bleeding events
between patients on DOACs versus warfarin in the
time-to-event analysis (Fig. 2, Mantel–Cox P = 0.15).
The rates of major bleeding were 7.2% per year with
DOACs vs. 11.4% per year with warfarin. Major bleed-
ing events occurred at a median of 12.0 (IQR 1.3–
30.8) months after initiation of anticoagulation. There
was no difference in classification of major bleeding
(Table 2), but numerically more warfarin patients, who
had major bleeding event, experienced bleeding at a
critical site or organ (38% vs. 11%). Approximately
10% of patients in both groups had a procedure
within 5 days prior to the major bleeding event.
Twenty-one patients had a major bleeding event on
warfarin therapy. Of these patients, 38% had a
supratherapeutic international normalized ratio (INR)
at the time of bleeding event (defined as an INR
greater than 3). The median INR at the time of bleed-
ing event was 2.5 (range 1.1–9.6).
The rates of composite bleeding were 19.4% per year
with DOAC vs. 20.8% per year with warfarin, and they
were not statistically different between groups in the
time-to-event analysis. New VTE occurred in 3.1% vs.
2.0% (P = 0.50) and stroke occurred in 5.1% vs. 1.0%
(P = 0.13) of warfarin and DOAC patients, respectively.
The median time to VTE or stroke was 371 days (IQR
159–813 days). The shortest onset to VTE was 10 days
for a patient taking apixaban. This patient was on a
CYP3A4 inducer, which may have led to subtherapeutic
apixaban levels. There was no difference between groups
in the number of patients that died during follow-up
(9.2% with warfarin vs. 7.1% with DOAC, P = 0.59).
None of the DOAC patients with a VTE or stroke were
underdosed for their level of kidney function.
Comparison of different DOAC agents
There was no statistical difference in the safety or effi-
cacy outcomes when comparing the three DOACs
(Table 3). There were only six patients on dabigatran
and no major bleeding events occurred on this agent.
Interestingly, 6.7% of patients on apixaban experienced
a major bleeding event versus 15.2% on rivaroxaban
(P = 0.19). When apixaban alone was compared to war-
farin there was a lower incidence of major bleeding
(6.7% vs. 21.4%, P = 0.014) and a trend toward lower
composite bleeding (21.7% vs. 34.7%, P = 0.08). Simi-
larly, when apixaban was compared to all other agents
(warfarin, dabigatran, and rivaroxaban), there was a
lower incidence of major bleeding (6.7% vs. 19.0%,
P = 0.027), but no difference in composite bleeding
(21.7% vs. 32.8%, P = 0.11). None of the patients that
experienced a major bleeding event were considered
overdosed based on their renal function at the time of
the bleed. There were no differences between any of the
agents regarding stroke and VTE events during antico-
agulation therapy.
Cox regression
Multivariable Cox regression analysis for associations
with time to major bleeding events is presented in
Table 4. In the model, safety of DOAC use was not
associated with an increased risk of bleeding when com-
pared to warfarin (HR 0.73, CI 0.27–1.95; P = 0.529)
even after controlling for the potential confounders.
Prior bleeding events (HR 3.86, CI 1.41–10.57;
P = 0.009) and having a deceased donor (HR 2.74, CI
1.16–6.45, P = 0.021) were significant risk factors for
major bleeding. Higher baseline Hgb levels were protec-
tive of bleeding (HR 0.66, CI 0.54–0.82; P < 0.001).
The Schoenfeld test for models meeting proportional
hazards showed agreement with hypotheses (v2 = 20.7,
P = 0.079). In our sensitivity analysis looking at those
without prior bleeding events, DOAC use was not more
or less protective than warfarin for major bleeding
events (HR 0.83, CI 0.26–2.67; P = 0.759). Again,
Transplant International 2020; 33: 740–751 743
ª 2020 Steunstichting ESOT. Published by John Wiley & Sons Ltd
DOACs vs Warfarin in kidney transplant
having a deceased donor was a hazard (HR 2.77, CI
1.07–7.13; P = 0.035) and higher baseline Hgb levels
were protective (HR 0.068, CI 0.54–0.86; P = 0.001).
Additionally, concomitant antiplatelet use was protective
(HR 0.35, CI 0.13–0.96; P = 0.042).
Discussion
In this single-center retrospective study, we evaluated
197 kidney transplant recipients who were either on
DOAC or warfarin therapy for the treatment of VTE or
Table 1. Baseline demographics and clinical characteristics.
Outcome All (n = 197) Warfarin (n = 98) DOAC (n = 99) P-value
Age, median (IQR) 62.2 (55.4–68.9) 62.3 (54.4–68.4) 62.0 (56.5–70.3) 0.52
Sex, n (%)
Male 133 (68) 62 (63) 71 (72) 0.21
Female 64 (33) 36 (37) 28 (28)
Race, n (%)
Caucasian 146 (74) 69 (70) 77 (78) 0.15
Black 38 (19) 24 (25) 14 (37)
Other 13 (7) 5 (39) 8 (8)
Reason for transplant, n (%)
DM (type I or II) 62 (32) 31 (32) 31 (31) 0.81
HTN 28 (14) 14 (14) 14 (14)
Polycystic kidney disease 26 (13) 13 (13) 13 (13)
Glomerulonephritis 16 (8) 11 (11) 5 (5)
IgA nephropathy 15 (8) 6 (6) 9 (9)
FSGS 11 (6) 6 (6) 5 (5)
SLE 6 (3) 3 (3) 3 (3)
Other/unknown 33 (17) 14 (14) 19 (19)
Donor type, n (%)
Deceased donor 104 (53) 57 (58) 47 (48) 0.13
Living donor 93 (47) 41 (42) 52 (53)
Calcineurin inhibitor, n (%)
Tacrolimus 151 (77) 74 (76) 77 (78) 0.87
Cyclosporine 41 (21) 21 (21) 20 (20)
Time from transplant to
initiation of anticoagulation,
years, median (IQR)
6.5 (2.6–11.2) 6.4 (1.6–12.5) 6.5 (2.8–10.8) 0.98
Follow-up, months, median (IQR) 12.3 (5.2–27.5) 13.1 (5.0–36.8) 11.0 (5.3–18.5) 0.15
Indication, n (%)
VTE 103 (52) 57 (58) 46 (47) 0.10
Atrial fibrillation 94 (48) 41 (42) 53 (54)
VTE index event, n (%)
Deep vein thrombosis 79 (48) 43 (42) 36 (36) 0.41
Pulmonary embolism 22 (40) 13 (13) 9 (9)
Both 2 (11) 1 (1) 1 (1)
CHA2DS2-VASc*, mean  SD 3.5  1.6 3.5  1.4 3.5  1.7 0.27
ATRIA*, mean  SD 3.4  2.0 3.6  2.1 3.2  1.9 0.21
Pertinent comorbidities, n (%)
Prior VTE event 33 (17) 15 (15) 18 (18) 0.59
Prior bleed 25 (13) 11 (11) 14 (14) 0.52
Stroke 19 (10) 10 (10) 9 (9) 0.79
Year anticoagulation started
2011–2013 33 (17) 25 (26) 8 (8) <0.001
2014 26 (13) 16 (16) 10 (10)
2015 34 (17) 23 (23) 11 (11)
2016 35 (18) 13 (13) 22 (22)
2017 33 (17) 17 (17) 16 (16)
2018 36 (18) 4 (4) 32 (32)
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primary prevention of thromboembolic events associ-
ated with nonvalvular atrial fibrillation. The groups had
similar baseline characteristics, with the exception of
baseline Hgb, concomitant antiplatelet use, and calendar
year when anticoagulation was started. Warfarin was the
predominantly used anticoagulant in the beginning of
the study period. Practice shifted from warfarin use to
DOAC use after 2013. This trend is consistent with
national prescribing data among the general population
and among patients with kidney disease [17,18].
In our study cohort, the overall incidence of compos-
ite bleeding was 29% with 15% of patients experiencing
a major bleed. The rates of major bleeding and compos-
ite bleeding in DOAC patients were 7.2% and 19.4%
per year, respectively. These rates are substantially
higher than those reported in the clinical trials of
DOAC therapy in nontransplant populations (major
bleed 0.6–3.6% and any bleed 5.6–18.2%) [19-24]. With
warfarin therapy, the rates were even higher for both
major and composite bleeding (11.4% and 20.8% per
year, respectively); however, they were not statistically
different from DOAC group. An earlier meta-analysis of
five randomized controlled trials for the treatment of
VTE found that DOACs significantly reduced risk of
major bleeding compared with warfarin (RR 0.60, 95%
CI 0.41–0.88) [25]. A more recent meta-analysis of 13
randomized controlled trials for stroke or systemic
embolism prevention in patients with atrial fibrillation
also found a significantly lower risk of major bleeding
with DOACs (OR 0.78, 95% CI 0.73–0.84) [26].
It is possible that the higher incidence of bleeding
seen in our study is due to the ability to capture bleed-
ing events utilizing a search feature or the ability to see
admissions for bleeding at outside institutions in the
electronic medical record. Additionally, surgical or pro-
cedure-related bleeding was possible in this study. Pro-
cedures that preceded bleeding events were captured.
Because of the lack of transplant specific definition for
Table 1. Continued.
Outcome All (n = 197) Warfarin (n = 98) DOAC (n = 99) P-value
Concomitant antiplatelet use, n (%) 96 (49) 56 (57) 40 (40) 0.02
Drug interactions present, n (%)
CYP3A4 and/or P-gp inhibitors
Diltiazem 15 (8) 5 (5) 10 (10) 0.29
Amiodarone 6 (3) 2 (2) 4 (4)
Itraconazole 2 (1) 2 (2) 0 (0)
Verapamil 1 (0.5) 1 (1.0) 0 (0)
Voriconazole 1 (0.5) 0 (0) 1 (1.0)
Diltiazem and amiodarone 2 (1.0) 0 (0) 2 (2.0)
CYP3A4 inducer
Carbamazepine 1 (0.5) 0 (0) 1 (1.0)
eGFR by MDRD-4, ml/min/1.73 m2, median (IQR) 52.4 (41.0–64.4) 50.0 (35.3–63.1) 54.5 (43.0–64.8) 0.68
eGFR <30 ml/min/1.73 m2 22 (11.2) 15 (15.3) 7 (7.1) 0.067
Hgb, g/dl, mean  SD 12  2 11.5  2.1 12.5  2.1 0.001
ATRIA, Anticoagulation and Risk Factors in Atrial Fibrillation; CYP, cytochrome P-450; DM, diabetes mellitus; DOAC, direct oral
anticoagulant; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; HTN, hypertension; IQR,
interquartile range; MDRD, modification of diet in renal disease study equation; P-gp, P-glycoprotein; SD, standard deviation;
SLE, systemic lupus erythematosus; VTE, venous thromboembolism.
*For atrial fibrillation patients only.
Time from anticoagulation initiation (months)
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DOAC
Warfarin
Mantel−Cox test P value 0.15
Figure 2 Kaplan–Meier plot for major bleeding event.
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major bleeding, we decided to use the nonsurgical
major bleeding definition because the median time from
transplant was 6.5 years. The bleeding definition will
need to be better defined in a kidney transplant popula-
tion in a prospective study.
In our study, more warfarin patients had major
bleeding at a critical site or organ (38% vs. 11%). This
was consistent with findings in nontransplant popula-
tions. The meta-analysis of VTE trials found a lower
risk of nonfatal bleeding at a critical site (RR 0.38, 95%
CI 0.23–0.62) and the meta-analysis of atrial fibrillation
trials found a lower risk for intracranial hemorrhage
with DOACs than warfarin (RR 0.50, 95% CI 0.42–
0.59) [25,26].
There is a limited amount of data examining DOAC
use in solid organ transplant recipients as most of the
reports are in abstracts or conference proceedings
(Table 5) [27-44]. The bleeding incidences in our
DOAC group were within the previously reported
ranges of composite bleeding (6–37%) and major
Table 3. Bleeding and thromboembolic outcomes.
Outcome, n (%) Warfarin (n = 98) All DOAC (n = 99) Apixaban (n = 60) Dabigatran (n = 6) Rivaroxaban (n = 33)
Composite bleed 34 (34.7) 24 (24.2) 13 (21.7) 2 (33.3) 9 (27.3)
Major bleed 21 (21.4) 9 (9.1) 4 (6.7)* 0 (0%) 5 (15.2)
CRNMB 14 (14.3) 16 (16.2) 9 (15) 2 (33.3) 5 (15.2)
VTE 3 (3.1) 2 (2.0) 1 (1.7) 0 (0) 1 (3.0)
Stroke 5 (5.1) 1 (1.0) 1 (1.7) 0 (0) 0 (0)
CRNMB, clinically relevant nonmajor bleeding; DOAC, direct oral anticoagulant; VTE, venous thromboembolism.
*P = 0.014 compared with the major bleeding incidence of warfarin (21.4%); P = 0.027 compared with the major bleeding
incidence of all the other agents (19.0%).
Table 2. Major bleeding.
Outcome All (n = 30) Warfarin (n = 21) DOAC (n = 9) P-value
Classification, n (%)
Bleeding at critical site/organ 9 (30.0) 8 (38.1) 1 (11.1) 0.13
pRBC ≥2 units 12 (40.0) 7 (33.3) 5 (55.5)
Decrease in Hgb ≥2 g/dl 9 (30.0) 6 (28.6) 3 (33)
Site of bleeding, n (%)
Gastrointestinal 12 (40.0) 8 (38.1) 4 (44.4) 0.13
Hematuria 2 (6.7) 0 (0) 2 (22.2)
Intracranial 1 (3.3) 1 (4.8) 0 (0)
Musculoskeletal 3 (10.0) 2 (9.5) 1 (11.1)
Pericardial 1 (3.3) 0 (0) 1 (11.1)
Retroperitoneal 6 (20) 6 (28.6) 0 (0)
Eye/ocular 1 (3.3) 1 (4.8) 0 (0)
Other/unknown 4 (13.3) 3 (14.3) 1 (11.1)
Procedure within 5 days, n (%) 3 (10.0) 2 (9.5) 1 (11.1) 0.67
Hgb at bleeding, g/dl, mean  SD 7.7  2.0 8.0  2.1 7.2  1.8 0.31
Indication, n (%)
Atrial fibrillation 20 (66.7) 13 (61.9) 7 (77.8) 0.40
VTE 10 (33.3) 8 (38.1) 2 (22.2)
Renal function
At baseline
eGFR, ml/min/1.73 m2, median (IQR) 50.1 (42.2–55.9) 46.4 (37.2–58.1) 53.3 (47.3–60.5) 0.20
At bleed
Dialysis, n (%) 3 (10.0) 3 (14.3) 0 (0) 0.53
eGFR, ml/min/1.73 m2, median (IQR) 42.7 (30.4–50.9) 42.0 (29.2–53.2) 45.0 (34.9–53.3) 0.57
DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; Hgb, hemoglobin; IQR, interquartile range; pRBC,
packed red blood cells; SD, standard deviation; VTE, venous thromboembolism.
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bleeding (0–23%). Our study does have a numerically
higher incidence of bleeding when compared to some of
the other studies which may be related to sample size,
duration of follow-up, and access to electronic medical
records from outside institutions. To our knowledge,
this is the largest study to date that compared DOACs
to warfarin in kidney transplant recipients.
In addition to the sparse data of DOAC use in trans-
plant recipients, there is even less data comparing DOAC
users to warfarin users among transplant recipients.
Comparative studies are limited to abstracts only. Santeu-
sanio et al. [39] found a higher incidence of clinically sig-
nificant bleeding with the warfarin group compared to
the DOAC group in liver transplant recipients (50% vs.
15%, P = 0.01). When Tremblay-Gravel et al. [42] com-
pared warfarin to DOACs in heart transplant recipients,
they found an increased risk of bleeding with warfarin
(OR 4.55, 95% CI 1.2–16.2). However, it should be noted
that baseline renal function was significantly worse in the
warfarin group with 43% of warfarin patients and 5% of
DOAC patients on dialysis. Hazelcorn et al. [31] found
no difference in major bleeding between warfarin and
DOAC groups (5% vs. 11%, P = 0.42) in various organ
transplant recipients, but the study was likely underpow-
ered to detect a difference. Although our study did not
find a difference in major bleeding incidence between all
DOACs and warfarin, we did find a lower incidence of
major bleeding with apixaban compared to warfarin
(6.7% vs. 21.4%, P = 0.014) in kidney transplant recipi-
ents. Although there is heterogeneity among these studies,
they do indicate a trend toward lower major bleeding risk
with DOACs compared to warfarin in solid organ trans-
plant recipients.
It is possible that the lower event rates seen with
DOAC agents are fueled by the low number of bleeding
events for patients on apixaban therapy. In our study,
there was a lower incidence of major bleeding when
apixaban was compared to warfarin alone and when
compared to a composite of warfarin, dabigatran, and
rivaroxaban. We found no difference in composite
bleeding event when apixaban was compared to any
other agents. Pasley et al. [38]. compared heart and
lung transplant recipients that were using apixaban to a
group of nonapixaban DOACs. They found no differ-
ence in major (0% vs. 1%) or composite bleeding (10%
vs. 15%, P = 0.75). Interestingly, McMurry et al. [36].
found a higher incidence of composite bleeding events
when rivaroxaban was compared to apixaban among all
solid organ transplant recipients (12% vs. 2%,
P = 0.006). In our study, rivaroxaban compared to
other DOACs was associated with a numerically higher
incidence of major bleeding, but this was not statisti-
cally significant (15.2% vs. 6.7%, P = 0.12). Solid organ
transplant recipients often have risk factors present that
increase their risk for bleeding. Specifically, transplant
recipients are at risk for developing chronic renal failure
and thus it is important to consider renal elimination
of DOAC agents. Of the DOACs currently approved for
the treatment of VTE and prevention of stroke, apixa-
ban relies the least on renal clearance (27%) [11-13].
This is potentially why there appears to be a lower inci-
dence of bleeding with apixaban.
Table 4. Multivariable cox regression: risk for major bleeding.
Variable HR (95% CI) P-value
DOAC use 0.73 (0.27–1.95) 0.529
Age (years) 1.00 (0.96–1.05) 0.835
Prior bleed 3.86 (1.41–10.57) 0.009
Concomitant antiplatelet use 0.49 (0.21–1.14) 0.097
eGFR <30 ml/min/1.73 m2 0.67 (0.21–2.10) 0.488
Atrial fibrillation 2.11 (0.94–4.77) 0.071
Deceased donor transplant 2.74 (1.16–6.45) 0.021
Hgb at initiation (g/dl) 0.66 (0.54–0.82) <0.001
Anticoagulation start 2014 vs. 2011–2013 1.07 (0.23–4.93) 0.934
Anticoagulation start 2015 vs. 2011–2013 2.18 (0.63–7.49) 0.217
Anticoagulation start 2016 vs. 2011–2013 1.44 (0.35–5.82) 0.612
Anticoagulation start 2017 vs. 2011–2013 0.99 (0.19–5.32) 0.994
Anticoagulation start 2018 vs. 2011–2013 2.55 (0.40–16.30) 0.321
CI, confidence interval; DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; Hgb, hemoglobin; HR, haz-
ard ratio.
Bolded variables are statistically significant with P < 0.05.
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There is some information suggesting a potential
interaction between DOACs and cyclosporine resulting
in increases of DOAC concentrations through inhibition
of P-gp [8]. However, this interaction is not significant
enough to require empiric dose adjustments [11-13].
Interestingly, DOACs are often dose adjusted in solid
organ transplant recipients whether or not it is sup-
ported by the approved labeling (Table 5).
Solid organ transplant recipients often undergo surveil-
lance or for-cause biopsy. Anticoagulation should be held
prior to organ biopsy to reduce the risk for bleeding
events. In our study, there was only one bleed (CRNMB)
following organ biopsy in a patient on apixaban. Despite
holding apixaban for one week prior to biopsy, the
patient developed hematuria postbiopsy leading to hospi-
talization. Hazelcorn et al. [31] found that 50% of major
bleeding events occurred after organ biopsy. However, it
is not clear how long anticoagulation was held prior to
biopsy. Another study described that protocol biopsies
were not performed in 50% of patients because of DOAC
use [28]. Prior studies have shown low rates of postbiopsy
bleeding among the transplant population. However,
many surveillance biopsies were canceled in these studies
indicating that providers may be uncomfortable perform-
ing biopsies for patients on DOAC.
In our Cox regression model, we accounted for dif-
ferences in baseline characteristics and found no associ-
ation between DOAC use and major bleeding (HR 0.73,
95% CI 0.27–1.95; P = 0.53). Prior bleeding events and
having a deceased donor were risk factors for major
bleeding. It is possible that deceased donor is a risk fac-
tor for bleeding because of the increased time spent on
dialysis compared with living donor kidney transplant
recipients. Patients on dialysis are known to have plate-
let dysfunction and are at increased risk of gastrointesti-
nal bleeding because of angiodysplasias [45,46]. After
transplant, it can take up to 2 years for platelet function
to normalize [45]. The combination of these factors is
one potential reason that deceased donor transplant
recipients may be at a higher risk for bleeding. How-
ever, it is important to note that the median time from
transplant in our study was 6.5 years and it is unlikely
that platelet dysfunction would persist in those patients
several years from transplant.
The incidence of VTE and stroke in this study is sim-
ilar to what has been reported in previous publications
of DOAC use in transplant recipients (Table 5). In fact,
the incidences of VTE and stroke on DOACs in our
study are substantially lower than other studies that
have reported inappropriate DOAC dose adjustments in
68% of patients (3% vs. 21%) [37].
As a retrospective single-center cohort study, there
are several limitations to this study. Data were depen-
dent on documentation in the medical record, which
may have resulted in underreporting of safety or efficacy
outcomes. If the patient presented to a local hospital
with a bleeding or thrombotic event, it is possible that
this information could have been missed. Because of the
retrospective nature, we were unable to capture fluctua-
tions in renal function and INR, changes in antiplatelet
therapy, drug–drug interactions, or adherence to antico-
agulation throughout the entire follow-up period.
Although our study is one of the largest to date looking
at DOAC use in transplant recipients, the sample size is
small making it difficult to detect a statistical difference
in all bleeding outcomes. There are several strengths to
be noted including the long follow-up period and that
DOAC use was compared with the historic standard of
care, warfarin. Additionally, both groups were similar in
regard to baseline characteristics with the exception of
lower Hgb and more frequent concomitant antiplatelet
use in the warfarin group.
Direct-acting oral anticoagulant therapy is often uti-
lized as an alternative to warfarin in solid organ trans-
plant recipients. Based on the results of our study,
DOACs had an acceptable safety and efficacy profile
compared with warfarin for the management of VTE
and prevention of stroke following nonvalvular atrial
fibrillation in kidney transplant recipients. However,
further studies are warranted to demonstrate that
DOACs are safe and effective alternatives to warfarin in
kidney transplant recipients.
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